From Wikipedia, the free encyclopedia
(Redirected from IIBR-100)
Vaccine candidate against COVID-19
![]() | You can help expand this article with text translated from the corresponding article in Hebrew. (November 2021) Click [show] for important translation instructions.
|
Pharmaceutical compound
![]() The former President of Israel, Reuven Rivlin, with the first vaccinator in Phase B of the IIBR-100 vaccine of the Israel Institute for Biological Research, at the Barzilai Medical Center. | |
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Viral vector |
Clinical data | |
Other names | Brilife |
Routes of administration | Intramuscular |
ATC code |
|
Identifiers | |
CAS Number |
Part of a series on the |
COVID-19 pandemic |
---|
![]() |
|
Medical response |
|
![]() |
BriLife, also known as IIBR-100, is a replication-competent recombinant VSV viral vectored COVID-19 vaccine candidate.[2][3][4][5] It was developed by the Israel Institute for Biological Research (IIBR).[2][6][7] The IIBR partnered with the US-based NRx Pharmaceuticals to complete clinical trials and commercialize the vaccine.[8][9] A study conducted in hamsters suggested that one dose of the vaccine was safe and effective at protecting against COVID-19.[10][4]
References
[edit]- ^ "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
- ^ a b Karpiński TM, Ożarowski M, Seremak-Mrozikiewicz A, Wolski H, Wlodkowic D (1 January 2021). "The 2020 race towards SARS-CoV-2 specific vaccines". Theranostics. 11 (4): 1690–1702. doi:10.7150/thno.53691. PMC 7778607. PMID 33408775.
- ^ Bezbaruah R, Borah P, Kakoti BB, Al-Shar'I NA, Chandrasekaran B, Jaradat DM, et al. (2021). "Developmental Landscape of Potential Vaccine Candidates Based on Viral Vector for Prophylaxis of COVID-19". Frontiers in Molecular Biosciences. 8: 635337. doi:10.3389/fmolb.2021.635337. PMC 8082173. PMID 33937326.
- ^ a b Pushparajah D, Jimenez S, Wong S, Alattas H, Nafissi N, Slavcev RA (March 2021). "Advances in gene-based vaccine platforms to address the COVID-19 pandemic". Advanced Drug Delivery Reviews. 170: 113–141. doi:10.1016/j.addr.2021.01.003. PMC 7789827. PMID 33422546.
- ^ Venkadapathi J, Govindarajan VK, Sekaran S, Venkatapathy S (9 June 2021). "A Minireview of the Promising Drugs and Vaccines in Pipeline for the Treatment of COVID-19 and Current Update on Clinical Trials". Frontiers in Molecular Biosciences. 8: 637378. doi:10.3389/fmolb.2021.637378. PMC 8219860. PMID 34179072.
- ^ Clinical trial number NCT04608305 for "Phase I/II Randomized, Multi-Center, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine (IIBR-100) in Adults" at ClinicalTrials.gov
- ^ Scarabel L, Guardascione M, Dal Bo M, Toffoli G (March 2021). "Pharmacological strategies to prevent SARS-CoV-2 infection and treat the early phases of COVID-19". International Journal of Infectious Diseases. 104: 441–451. doi:10.1016/j.ijid.2021.01.035. PMC 7816887. PMID 33476760.
- ^ Rabinovitch A, Williams D (12 July 2021). Grebler D (ed.). "Israel partners with NRx Pharmaceuticals to commercialize COVID vaccine". Reuters. Retrieved 10 November 2021.
- ^ "Israeli-produced vaccine shipped to Georgia for Phase II trial". i24 News. 15 August 2021. Retrieved 10 November 2021.
- ^ Yahalom-Ronen Y, Tamir H, Melamed S, Politi B, Shifman O, Achdout H, et al. (December 2020). "A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge". Nature Communications. 11 (1): 6402. doi:10.1038/s41467-020-20228-7. PMC 7745033. PMID 33328475.
External links
[edit]- IIBR-100 entry at Stanford Medicine
- Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine

Scholia has a profile for BriLife (Q100694835).
Wikimedia Commons has media related to BriLife.
Development | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Classes | |||||||||||
Administration | |||||||||||
Vaccines |
| ||||||||||
Inventors/ researchers | |||||||||||
Controversy | |||||||||||
Related | |||||||||||
|
![]() | This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |
![]() | This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it. |
Retrieved from "https://teknopedia.ac.id/w/index.php?title=BriLife&oldid=1256024376"
Hidden categories:
- Articles with short description
- Short description is different from Wikidata
- Use dmy dates from April 2021
- Science and technology articles needing translation from Hebrew Wikipedia
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drugs that are a vaccine
- Commons category link is on Wikidata
- All stub articles
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url